DE3650538D1 - Interleukin-4 protein mit bcgf- und tcgf-aktivität gegenüber menschlichen zellen (menschliches interleukin-4) - Google Patents

Interleukin-4 protein mit bcgf- und tcgf-aktivität gegenüber menschlichen zellen (menschliches interleukin-4)

Info

Publication number
DE3650538D1
DE3650538D1 DE3650538T DE3650538T DE3650538D1 DE 3650538 D1 DE3650538 D1 DE 3650538D1 DE 3650538 T DE3650538 T DE 3650538T DE 3650538 T DE3650538 T DE 3650538T DE 3650538 D1 DE3650538 D1 DE 3650538D1
Authority
DE
Germany
Prior art keywords
interleukin
bcgf
protein
activity against
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3650538T
Other languages
English (en)
Other versions
DE3650538T2 (de
Inventor
Frank Lee
Takashi Yokota
Ken-Ichi Arai
Timothy Mosmann
Donna Rennick
Craig Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/843,958 external-priority patent/US5552304A/en
Priority claimed from US06/908,215 external-priority patent/US5017691A/en
Application filed by Schering Biotech Corp filed Critical Schering Biotech Corp
Application granted granted Critical
Publication of DE3650538D1 publication Critical patent/DE3650538D1/de
Publication of DE3650538T2 publication Critical patent/DE3650538T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Fertilizers (AREA)
  • Auxiliary Devices For Music (AREA)
DE3650538T 1985-11-19 1986-11-19 Interleukin-4 protein mit bcgf- und tcgf-aktivität gegenüber menschlichen zellen (menschliches interleukin-4) Expired - Lifetime DE3650538T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US79966885A 1985-11-19 1985-11-19
US79966985A 1985-11-19 1985-11-19
US06/843,958 US5552304A (en) 1985-11-19 1986-03-25 CDNA Clones coding for human protein exhibiting a broad cellular activity spectrum (human interleukin-4)
US88155386A 1986-07-03 1986-07-03
US06/908,215 US5017691A (en) 1986-07-03 1986-09-17 Mammalian interleukin-4
PCT/US1986/002464 WO1987002990A1 (en) 1985-11-19 1986-11-19 Mammalian interleukin-4

Publications (2)

Publication Number Publication Date
DE3650538D1 true DE3650538D1 (de) 1996-08-08
DE3650538T2 DE3650538T2 (de) 1996-12-12

Family

ID=27542219

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3650538T Expired - Lifetime DE3650538T2 (de) 1985-11-19 1986-11-19 Interleukin-4 protein mit bcgf- und tcgf-aktivität gegenüber menschlichen zellen (menschliches interleukin-4)
DE3650751T Expired - Lifetime DE3650751T2 (de) 1985-11-19 1986-11-19 Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3650751T Expired - Lifetime DE3650751T2 (de) 1985-11-19 1986-11-19 Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung

Country Status (23)

Country Link
EP (3) EP0675136B1 (de)
JP (2) JP2557361B2 (de)
KR (1) KR940007773B1 (de)
CN (1) CN1020472C (de)
AT (2) ATE198754T1 (de)
AU (1) AU610057B2 (de)
CZ (1) CZ414191A3 (de)
DE (2) DE3650538T2 (de)
DK (1) DK371087A (de)
ES (2) ES2153444T3 (de)
FI (1) FI102075B (de)
GR (1) GR3021198T3 (de)
HK (2) HK1005594A1 (de)
HU (1) HU208710B (de)
IE (1) IE80828B1 (de)
IL (1) IL80678A (de)
MY (1) MY101972A (de)
NO (1) NO301234B1 (de)
NZ (1) NZ218332A (de)
OA (1) OA08947A (de)
PT (1) PT83761B (de)
SK (1) SK414191A3 (de)
WO (1) WO1987002990A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0740943B2 (ja) * 1985-09-30 1995-05-10 佑 本庶 新規なポリペプチドをコードするｄｎａ及びその製造方法
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5912136A (en) * 1985-11-19 1999-06-15 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5700915A (en) * 1985-11-19 1997-12-23 Schering Corporations Human interleukin immunopurification processes
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
EP0335900A4 (en) * 1986-12-19 1990-12-27 Immunex Corporation Human interleukin-4 muteins
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
KR890701759A (ko) * 1987-07-29 1989-12-21 스테이너 브이. 칸스태드 에스케리키아 콜라이내에서 발현된 사람 인터루킨-4의 정제방법
JPH02485A (ja) * 1987-08-03 1990-01-05 Yuu Honshiyo 新規なヒトインターロイキン４、該因子を発現させるための組換えベクター及びそのベクターにより形質転換された形質転換体
DE3882611T2 (de) * 1987-08-03 1993-12-23 Tasuku Honjo Menschliches Interleukin-4, Expressionsvektoren dafür und diese enthaltende Transformanten.
KR900700132A (ko) * 1988-02-02 1990-08-11 에릭 에스. 딕커 면역 글로불린 e 반응 억제 방법
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB2218420B (en) * 1988-04-12 1992-07-15 British Bio Technology Synthetic gene encoding interleukin 4
JPH02504284A (ja) * 1988-05-13 1990-12-06 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 抗原、および、抗イディオタイプ抗体、または抗原に対する細胞受容体に特異的な抗体に共通のアミノ酸配列に由来する免疫原および生物学的活性ペプチド
US4958007A (en) * 1988-05-17 1990-09-18 Schering-Plough Corp. Extraction of human interleukin-4- from bacteria
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1990006765A1 (en) * 1988-12-21 1990-06-28 Schering Corporation Use of interleukin-4 for lowering blood glucose levels and/or effecting weight reduction
WO1990007932A1 (en) * 1989-01-20 1990-07-26 The University Of Melbourne Fibrinolysis
US5077388A (en) * 1990-05-31 1991-12-31 Schering Corporation Purification of human interleukin-4 from a secreted escherichia coli mutant
EP0502080A4 (en) * 1989-11-21 1993-02-10 The University Of Melbourne Anti-inflammatory compositions and methods
SE465039B (sv) * 1989-11-23 1991-07-15 Chemrec Ab Saett att framstaella koklutar med hoeg sulfiditet foer sulfatmassakokning
US5188827A (en) * 1989-12-18 1993-02-23 Schering Corporation Use of interleukin-4- for lowering blood-cholesterol levels
MX9203401A (es) 1989-12-20 1992-07-01 Schering Corp Anticuerpos antagonistas de la interleukina-4 humana.
MY108672A (en) * 1990-03-21 1996-10-31 Schering Corp Use of il-4 to enhance immune responce to infectious antigenic challenges.
AU9161591A (en) * 1990-12-19 1992-07-22 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
CA2099263C (en) * 1991-01-10 1997-03-11 Martin A. Schwarz Use of il-4 to enhance the reparative phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
AUPN481295A0 (en) * 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
AU745161B2 (en) * 1998-05-12 2002-03-14 Isis Pharmaceuticals, Inc. Modulation of molecular interaction sites on RNA and other biomolecules
AUPQ005399A0 (en) * 1999-04-29 1999-05-27 Medvet Science Pty. Ltd. Agonists or antagonists for haemopoietic growth factors
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
CN103501805B (zh) 2011-01-18 2018-09-14 比奥尼斯有限责任公司 调节γ-C-细胞因子活性的组合物及方法
CN102212888A (zh) * 2011-03-17 2011-10-12 靳海峰 一种基于高通量测序的免疫组库构建方法
CN108350032A (zh) 2015-10-09 2018-07-31 比奥尼斯有限责任公司 调节γC-细胞因子活性

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US799668A (en) * 1905-05-29 1905-09-19 Albert R Pritchard Dough kneader and mixer.
US799669A (en) * 1905-07-27 1905-09-19 Eugene S Regnier Combined cutting and raking implement.
US843958A (en) * 1905-11-20 1907-02-12 Whitehead & Hoag Co Key-ring tag.
US4613459A (en) * 1982-10-20 1986-09-23 Dana-Farber Cancer Institute Lymphocyte growth factor
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
WO1987004723A1 (en) * 1986-02-11 1987-08-13 Board Of Regents, The University Of Texas System Recombinant human b-cell growth factor
ZA872781B (en) * 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
EP0335900A4 (en) * 1986-12-19 1990-12-27 Immunex Corporation Human interleukin-4 muteins

Also Published As

Publication number Publication date
JP2557361B2 (ja) 1996-11-27
AU6733487A (en) 1987-06-02
HK1008823A1 (en) 1999-05-21
NO872988D0 (no) 1987-07-17
CN1020472C (zh) 1993-05-05
EP0249613B1 (de) 1996-07-03
DK371087A (da) 1987-09-21
IL80678A0 (en) 1987-02-27
IE80828B1 (en) 1999-03-10
NO301234B1 (no) 1997-09-29
FI873141A0 (fi) 1987-07-16
ATE140009T1 (de) 1996-07-15
HU208710B (en) 1993-12-28
HK1005594A1 (en) 1999-01-15
EP0675136B1 (de) 2001-01-17
EP0230107A1 (de) 1987-07-29
GR3021198T3 (en) 1996-12-31
DK371087D0 (da) 1987-07-16
DE3650538T2 (de) 1996-12-12
ES2088858T3 (es) 1996-10-01
PT83761B (pt) 1989-06-30
NZ218332A (en) 1993-04-28
WO1987002990A1 (en) 1987-05-21
PT83761A (en) 1986-12-01
IL80678A (en) 1999-05-09
EP0675136A2 (de) 1995-10-04
IE863042L (en) 1987-05-19
MY101972A (en) 1992-02-29
FI102075B1 (fi) 1998-10-15
DE3650751D1 (de) 2001-02-22
ATE198754T1 (de) 2001-02-15
DE3650751T2 (de) 2001-08-02
CN86108579A (zh) 1988-01-27
FI102075B (fi) 1998-10-15
FI873141A (fi) 1987-07-16
ES2153444T3 (es) 2001-03-01
EP0249613A1 (de) 1987-12-23
HUT43630A (en) 1987-11-30
JP2568394B2 (ja) 1997-01-08
JPH0884591A (ja) 1996-04-02
EP0675136A3 (de) 1996-03-13
JPS63501401A (ja) 1988-06-02
SK414191A3 (en) 1995-07-11
CZ414191A3 (en) 1993-04-14
AU610057B2 (en) 1991-05-16
NO872988L (no) 1987-09-18
OA08947A (en) 1990-11-30
KR940007773B1 (ko) 1994-08-25

Similar Documents

Publication Publication Date Title
DE3650538D1 (de) Interleukin-4 protein mit bcgf- und tcgf-aktivität gegenüber menschlichen zellen (menschliches interleukin-4)
ATE246246T1 (de) Herstellung von hämoglobin und analogen davon in nicht-erythrozytzellen
DE3873397D1 (de) Bifunktionelle proteine.
ES533485A0 (es) Procedimiento para producir un vehiculo de expresion de adn-replicable.
HUT44615A (en) Process for preparing gm-cst protein and its derivatives
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SCHERING CORP., KENILWORTH, N.J., US